Otsuka M, Mori T
Department of Internal Medicine, Asanogawa General Hospital.
Rinsho Ketsueki. 1990 May;31(5):584-8.
Allogeneic bone marrow transplantation (BMT) has been used successfully to treat patients with hematological malignancies. However, interstitial pneumonia has remained a major complication following BMT. We investigated the possibility of immune transfer in recipients treated with BMT from immunized donors. Bone marrow donors were vaccinated with tetanus toxoid (TT) before marrow harvest. After BMT, serum IgG anti-TT antibody titer and in vitro IgG anti-TT antibody production in recipients were assayed sequentially. IgG anti-TT antibody titer in serum increased from about day 20 after BMT. In addition, spontaneous IgG anti-TT antibody producing B cells and TT antigen-specific memory B cells derived from donors were also detected in peripheral blood and bone marrow of recipients from about day 60. We therefore considered that antigen-specific immunity of bone marrow donors is transferable to recipients with BMT, and the immunity continued for a long time in the recipients after BMT. The effectiveness of cytomegalovirus (CMV) vaccine on antibody production was next investigated in healthy adults. Live vaccine induced the production of humoral antibody but envelope vaccine did not. These results indicate that more effective procedure should be needed for the use of envelope vaccine.
异基因骨髓移植（BMT）已成功用于治疗血液系统恶性肿瘤患者。然而，间质性肺炎仍然是BMT后的主要并发症。我们研究了用来自免疫供体的BMT治疗的受体中免疫转移的可能性。骨髓供体在采集骨髓前接种破伤风类毒素（TT）。BMT后，依次检测受体血清中IgG抗TT抗体滴度和体外IgG抗TT抗体产生情况。血清中IgG抗TT抗体滴度在BMT后约第20天开始升高。此外，从大约第60天起，在受体的外周血和骨髓中也检测到了来自供体的自发产生IgG抗TT抗体的B细胞和TT抗原特异性记忆B细胞。因此，我们认为骨髓供体的抗原特异性免疫可转移至接受BMT的受体，且该免疫在BMT后的受体中持续很长时间。接下来，我们在健康成年人中研究了巨细胞病毒（CMV）疫苗对抗体产生的有效性。活疫苗诱导了体液抗体的产生，但包膜疫苗没有。这些结果表明，使用包膜疫苗需要更有效的程序。
